EPAS1 and nonpapillary renal cell carcinoma: This may therapeutically represent benefits since HIF2α-inhibitors are only effective in a small group of ccRCC patients, and a large cohort of ccRCC patients have pre-existing or acquired resistance to HIF2α-inhibitors [49,77].